{deleted text} shows text that was in HB0230 but was deleted in HB0230S01.

inserted text shows text that was not in HB0230 but was inserted into HB0230S01.

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

Representative Jennifer Dailey-Provost proposes the following substitute bill:

#### CENTER FOR MEDICAL CANNABIS RESEARCH

2023 GENERAL SESSION STATE OF UTAH

Chief Sponsor: Jennifer { Dailey-Provost} Dailey-Provost Senate Sponsor:

#### **LONG TITLE**

#### **General Description:**

This bill creates the Center for Medical Cannabis Research.

#### **Highlighted Provisions:**

This bill:

- defines terms;
- \* {abolishes} modifies membership requirements for members of the Cannabis Research Review Board;
- creates the Center for Medical Cannabis Research (center) within the University of Utah;
- requires the Department of Health and Human Services to work with the center to create guidance on medical cannabis use;
- allows the center to be funded by the Qualified Patient Enterprise Fund; and

• establishes the center's duties. Money Appropriated in this Bill: None **Other Special Clauses:** None **Utah Code Sections Affected: AMENDS:** <del>{4-41a-102}</del>**26-61-201**, as last amended by Laws of Utah 2022, <del>{Chapters 290,}</del> Chapter 452 {26-61a-102, as last amended by Laws of Utah 2022, Chapters 290, 452  $\frac{26-61a-105}{26-61a-109}$ , as last amended by Laws of Utah  $\frac{2022}{202}$ , Chapter 452 **26-61a-201**, as last amended by Laws of Utah 2022, Chapters 198, 290 and 452 +2019, First Special Session, Chapter 5 26-61a-703, as last amended by Laws of Utah 2022, Chapter 97 **ENACTS: 26-61a-117**, Utah Code Annotated 1953 **53B-17-1401**, Utah Code Annotated 1953 **53B-17-1402**. Utah Code Annotated 1953 **REPEALS: 26-61-101**, as enacted by Laws of Utah 2017, Chapter 398 **26-61-102**, as last amended by Laws of Utah 2022, Chapter 452 **26-61-103**, as enacted by Laws of Utah 2017, Chapter 398 **26-61-201**, as last amended by Laws of Utah 2022, Chapter 452 26-61-202, as last amended by Laws of Utah 2022, Chapter 415 *Be it enacted by the Legislature of the state of Utah:* 


```
Section 1. Section {4-41a-102}26-61-201 is amended to read:
```


**4-41a-102. Definitions.** 

As used in this chapter:

(1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be injurious to health, including:

(a) martinidas
(a) pesticides;
(b) heavy metals;
(c) solvents;
(d) microbial life;
(e) toxins; or
——————————————————————————————————————
[(2) "Cannabis Research Review Board" means the Cannabis Research Review Board
created in Section 26-61-201.]
[(3)] (2) "Cannabis" means the same as that term is defined in Section 26-61a-102.
[(4)] (3) "Cannabis concentrate" means:
(a) the product of any chemical or physical process applied to naturally occurring
biomass that concentrates or isolates the cannabinoids contained in the biomass; and
(b) any amount of a natural, derivative, or synthetic cannabinoid in the synthetic
cannabinoid's purified state.
[(5)] (4) "Cannabis cultivation byproduct" means any portion of a cannabis plant that
not intended to be sold as a cannabis plant product.
[(6)] (5) "Cannabis cultivation facility" means a person that:
(a) possesses cannabis;
(b) grows or intends to grow cannabis; and
(c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis
processing facility, or a medical cannabis research licensee.
[(7)] (6) "Cannabis cultivation facility agent" means an individual who:
(a) is an employee of a cannabis cultivation facility; and
(b) holds a valid cannabis production establishment agent registration card.
[(8)] (7) "Cannabis derivative product" means a product made using cannabis
<del>concentrate.</del>
[(9)] (8) "Cannabis plant product" means any portion of a cannabis plant intended to b
sold in a form that is recognizable as a portion of a cannabis plant.
[(10)] (9) "Cannabis processing facility" means a person that:
(a) acquires or intends to acquire cannabis from a cannabis production establishment;
(b) possesses cannabis with the intent to manufacture a cannabis product;
f 1






- [(33)] (32) "Medicinal dosage form" means the same as that term is defined in Section <del>26-61a-102.</del> [(34)] (33) "Qualified medical provider" means the same as that term is defined in Section 26-61a-102. [(35)] (34) "Qualified Production Enterprise Fund" means the fund created in Section 4-41a-104. [(36)] (35) "Recommending medical provider" means the same as that term is defined in Section 26-61a-102. [(37)] (36) "Research university" means the same as that term is defined in Section 53B-7-702 and a private, nonprofit college or university in the state that: (a) is accredited by the Northwest Commission on Colleges and Universities; (b) grants doctoral degrees; and (c) has a laboratory containing or a program researching a schedule I controlled substance described in Section 58-37-4. [(38)] (37) "State electronic verification system" means the system described in Section <del>26-61a-103.</del> [(39)] (38) "Synthetic cannabinoid" means any cannabinoid that: (a) was chemically synthesized from starting materials other than a naturally occurring cannabinoid; and (b) is not a derivative cannabinoid. [(40)] (39) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in Section 4-41-102. -[(41)] (40) "THC analog" means the same as that term is defined in Section 4-41-102. [(42)] (41) "Total composite tetrahydrocannabinol" means all detectable forms of tetrahydrocannabinol. [(43)] (42) "Total tetrahydrocannabinol" or "total THC" means the same as that term is defined in Section 4-41-102. 26-61-201. Cannabis Research Review Board.
  - (1) There is created the Cannabis Research Review Board within the department.
- (2) The department shall appoint, in consultation with a professional association based in the state that represents physicians, seven members to the Cannabis Research Review Board


as follows:


- (a) three individuals who are medical research professionals; and
- (b) four physicians who:
- (i) are qualified medical providers; and
- (ii) each have at least 150 patients with a medical cannabis patient card at the time of appointment.
- (3) The department shall ensure that at least one of the board members appointed under Subsection (2) is a member of the Controlled Substances Advisory Committee created in Section 58-38a-201.
- (4) (a) Four of the board members appointed under Subsection (2) shall serve an initial term of two years and three of the board members appointed under Subsection (2) shall serve an initial term of four years.
  - (b) Successor board members shall each serve a term of four years.
- (c) A board member appointed to fill a vacancy on the board shall serve the remainder of the term of the board member whose departure created the vacancy.
  - (5) The department may remove a board member without cause.
  - (6) The board shall:
- (a) nominate a board member to serve as chairperson of the board by a majority vote of the board members; and
- (b) meet as often as necessary to accomplish the duties assigned to the board under this chapter.
  - (7) Each board member, including the chair, has one vote.
  - (8) (a) A majority of board members constitutes a quorum.
- (b) A vote of a majority of the quorum at any board meeting is necessary to take action on behalf of the board.
- (9) A board member may not receive compensation for the member's service on the board, but may, in accordance with rules adopted by the board in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, receive:
  - (a) per diem at the rate established under Section 63A-3-106; and
  - (b) travel expenses at the rate established under Section 63A-3-107.
  - (10) If a board member appointed under Subsection (2)(b) does not meet the


qualifications of Subsection (2)(b) before July 1, 2022: (a) the board member's seat is vacant; and (b) the department shall fill the vacancy in accordance with this section. Section 2. Section  $\frac{26-61a-102}{26-61a-109}$  is amended to read: 26-61a-102. Definitions. As used in this chapter: (1) "Active tetrahydrocannabinol" means THC, any THC analog, and tetrahydrocannabinolic acid. [(2) " Cannabis Research Review Board" means the Cannabis Research Review Board created in Section 26-61-201.] [(3)] (2) "Cannabis" means marijuana. [(4)] (3) "Cannabis cultivation facility" means the same as that term is defined in Section 4-41a-102. [(5)] (4) "Cannabis processing facility" means the same as that term is defined in Section 4-41a-102. [(6)] (5) "Cannabis product" means a product that: (a) is intended for human use; and (b) contains cannabis or any tetrahydrocannabinol or THC analog in a total concentration of 0.3% or greater on a dry weight basis. [(7)] (6) "Cannabis production establishment" means the same as that term is defined in Section 4-41a-102. [(8)] (7) "Cannabis production establishment agent" means the same as that term is defined in Section 4-41a-102. [(9)] (8) "Cannabis production establishment agent registration card" means the same as that term is defined in Section 4-41a-102. -[(10)] (9) "Community location" means a public or private elementary or secondary school, a church, a public library, a public playground, or a public park. [(11)] (10) "Conditional medical cannabis card" means an electronic medical cannabis card that the department issues in accordance with Subsection 26-61a-201(1)(b) to allow an applicant for a medical cannabis card to access medical cannabis during the department's


review of the application.



























- (8) Any individually identifiable health information contained in a petition that the Compassionate Use Board or department receives under this section is a protected record in accordance with Title 63G, Chapter 2, Government Records Access and Management Act.
- [(9) The Compassionate Use Board shall annually report the board's activity to the Cannabis Research Review Board.]
- **?** 26-61a-109. **{}** Qualified Patient Enterprise Fund -- Creation -- Revenue neutrality.
- (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund."
  - (2) The fund created in this section is funded from:
  - (a) money the department deposits into the fund under this chapter;
  - (b) appropriations the Legislature makes to the fund; and
  - (c) the interest described in Subsection (3).
  - (3) Interest earned on the fund shall be deposited into the fund.
- [(4) The department may only use money in the fund to fund the department's responsibilities under this chapter {..}]
  - (4) Money deposited into the fund may only be used by:
- (a) the department to accomplish the department's responsibilities described in this chapter; and
- (b) the Center for Medical Cannabis Research created in Section 53B-17-1402 to accomplish the Center for Medical Cannabis Research's responsibilities.
- (5) The department shall set fees authorized under this chapter in amounts that the department anticipates are necessary, in total, to cover the department's cost to implement this chapter.

Section \(\frac{44}{2}\). Section \(\frac{26-61a-201}{26-61a-201}\)\(\frac{26-61a-201}{26-61a-201}\)\(\frac{26-61a-201}{26-61a-117}\).\(\frac{26-61a-201}{26-61a-201}\)\(\frac{26-61a-201}{26-61a-201}


{(1) (a) } The department{ shall, within 15 days after the day on which an individual who satisfies the eligibility criteria in this section or Section 26-61a-202 submits an application in accordance with this section or Section 26-61a-202:




- (ii) the individual is a Utah resident; (iii) the individual's recommending medical provider recommends, in consultation with the Center for Medical Cannabis Research created in Section 53B-17-1402, shall: (1) develop evidence-based guidance for treatment with medical cannabis fin accordance with Subsection (4): (iv) the individual signs an acknowledgment stating that the individual received the information} based on the latest medical research that shall include: (a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis; (b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and (c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration; and (2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding: (a) the evidence-based guidance for treatment with medical cannabis described in Subsection (<del>{9}); and</del> (v) the individual pays to the department a fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504. (b) (i) An individual is eligible for a\{1\)(a); (b) relevant warnings and safety information related to medical cannabis <del>{guardian</del>} card if the individual: (A) is at least 18 years old; (B) is a Utah resident;
- (C) is the parent or legal guardian of a minor for whom the minor's qualified medical provider recommends a use; and
- (c) other topics related to medical cannabis {treatment, the individual petitions the Compassionate Use Board under Section 26-61a-105, and the Compassionate Use Board recommends department approval of the petition;
- (D) the individual signs an acknowledgment stating that the individual received the information described in Subsection (9);

(E) pays to the department a fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the criminal background check described in Section 26-61a-203; and (F) the individual has not been convicted of a misdemeanor or felony drug distribution offense under either state or federal law, unless the individual completed any imposed sentence six months or more before the day on which the individual applies for a medical cannabis guardian card. (ii) The department shall notify the Department of Public Safety of each individual that the department registers for a medical cannabis guardian card. (c) (i) A minor is eligible for a provisional patient card if: (A) the minor has a qualifying condition; (B) the minor's qualified medical provider recommends a medical cannabis treatment to address the minor's qualifying condition; (C) one of the minor's parents or legal guardians petitions the Compassionate Use Board under Section 26-61a-105, and the Compassionate Use Board recommends department approval of the petition; and (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d) who is eligible for a medical cannabis caregiver card under Section 26-61a-202. (ii) The department shall automatically issue a provisional patient card to the minor described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis guardian card to the minor's parent or legal guardian. (d) Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of servicing the designation, if the parent or legal guardian of a minor described in Subsections (2)(c)(i)(A) through (C) does not qualify for a medical cannabis guardian card under Subsection (2)(b), the parent or legal guardian may designate up to two caregivers in accordance with Subsection 26-61a-202(1)(c) to ensure that the minor has adequate and safe access to the recommended medical cannabis treatment. (3) (a) An individual who is eligible for a medical cannabis card described in Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the

department:





original medical cannabis card, the recommending medical provider determines that the patient has been stabilized on the medical cannabis treatment and a one-year renewal period is justified.

- (b) (i) A medical cannabis card that the department issues in relation to a terminal illness described in Section 26-61a-104 expires after one year.
- (ii) The recommending medical provider may revoke a recommendation that the provider made in relation to a terminal illness described in Section 26-61a-104 if the medical cannabis cardholder no longer has the terminal illness.
- (c) A medical cannabis card that the department issues in relation to acute pain as described in Section 26-61a-104 expires 30 days after the day on which the department first issues a conditional or full medical cannabis card.
- (6) (a) A medical cannabis patient card or a medical cannabis guardian card is renewable if:
- (i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or (b); or
- (ii) the cardholder received the medical cannabis card through the recommendation of the Compassionate Use Board under Section 26-61a-105.
- (b) The recommending medical provider who made the underlying recommendation for the card of a cardholder described in Subsection (6)(a) may renew the cardholder's card through phone or video conference with the cardholder, at the recommending medical provider's discretion.
- (c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b) shall pay to the department a renewal fee in an amount that:
- (i) subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504; and
- (ii) may not exceed the cost of the relatively lower administrative burden of renewal in comparison to the original application process.
- (d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional patient card renews automatically at the time the minor's parent or legal guardian renews the parent or legal guardian's associated medical cannabis guardian card.
  - (7) (a) A cardholder under this section shall carry the cardholder's valid medical

#### cannabis card with the patient's name.

- (b) (i) A medical cannabis patient cardholder or a provisional patient cardholder may purchase, in accordance with this chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.
- (ii) A cardholder under this section may possess or transport, in accordance with this chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.
- (iii) To address the qualifying condition underlying the medical cannabis treatment recommendation:
- (A) a medical cannabis patient cardholder or a provisional patient cardholder may use cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form, or a medical cannabis device; and
- (B) a medical cannabis guardian cardholder may assist the associated provisional patient cardholder with the use of cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form, or a medical cannabis device.
- (8) The department may revoke a medical cannabis card that the department issues under this section if the cardholder:
- (a) violates this chapter; or
- (b) is convicted under state or federal law of, after March 17, 2021, a drug distribution offense.
- (9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to provide information regarding the following to an individual receiving a medical cannabis card:
- (a) risks associated with medical cannabis treatment;
- (b) the fact that a condition's listing as a qualifying condition does not suggest that medical cannabis treatment is an effective treatment or cure for that condition, as described in Subsection 26-61a-104(1); and
  - (c) other relevant warnings and safety information that the department determines.
- (10) The department may establish procedures by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance

#### provisions of this section.

- (11) (a) On or before September 1, 2021, the department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to allow an individual from another state to register with the department in order to purchase medical cannabis or a medical cannabis device from a medical cannabis pharmacy while the individual is visiting the state.
- (b) The department may only provide the registration process described in Subsection (11)(a):
  - (i) to a nonresident patient; and
- (ii) for no more than two visitation periods per calendar year of up to 21 calendar days per visitation period.
- (12) (a) A person may submit to the department a request to conduct a research study using medical cannabis cardholder data that the state electronic verification system contains.
- (b) The department shall review a request described in Subsection (12)(a) to determine whether an institutional review board[, as that term is defined in Section 26-61-102,] could approve the research study.
- (c) At the time an individual applies for a medical cannabis card, the department shall notify the individual:
- (i) of how the individual's information will be used as a cardholder;
- (ii) that by applying for a medical cannabis card, unless the individual withdraws consent under Subsection (12)(d), the individual consents to the use of the individual's information for external research; and
- (iii) that the individual may withdraw consent for the use of the individual's information for external research at any time, including at the time of application.
- (d) An applicant may, through the medical cannabis card application, and a medical cannabis cardholder may, through the state central patient portal, withdraw the applicant's or cardholder's consent to participate in external research at any time.
- (e) The department may release, for the purposes of a study described in this Subsection (12), information about a cardholder under this section who consents to participate under Subsection (12)(c).
  - (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of

#### consent:

- (i) applies to external research that is initiated after the withdrawal of consent; and
- (ii) does not apply to research that was initiated before the withdrawal of consent.
- (g) The department may establish standards for a medical research study's validity, by rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
- (13) The department shall record the issuance or revocation of a medical cannabis card under this section in the controlled substance database.

Section 5 use as determined by the department.

Section 4. Section 26-61a-703 is amended to read:

#### 26-61a-703. Report.

- (1) By the November interim meeting each year beginning in 2020, the department shall report to the Health and Human Services Interim Committee on:
- (a) the number of applications and renewal applications filed for medical cannabis cards;
  - (b) the number of qualifying patients and designated caregivers;
  - (c) the nature of the debilitating medical conditions of the qualifying patients;
  - (d) the age and county of residence of cardholders;
  - (e) the number of medical cannabis cards revoked;
  - (f) the number of practitioners providing recommendations for qualifying patients;
  - (g) the number of license applications and renewal license applications received;
  - (h) the number of licenses the department has issued in each county;
  - (i) the number of licenses the department has revoked;
- (j) the quantity of medical cannabis shipments that the state central patient portal facilitates;
- (k) the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy;
- (l) the expenses incurred and revenues generated from the medical cannabis program; and
  - (m) an analysis of product availability in medical cannabis pharmacies.
- (2) The report shall include information provided by the Center for Medical Cannabis Research described in Section 53B-17-1402.

- [(2)] (3) The department may not include personally identifying information in the report described in this section.
- [(3)] (4) During the 2022 legislative interim, the department shall report to the working group described in Section 36-12-8.2 as requested by the working group.

Section  $\frac{(6)}{5}$ . Section 53B-17-1401 is enacted to read:

#### **CHAPTER 17. UNIVERSITY OF UTAH**

#### Part 14. Center for Medical Cannabis Research

#### **53B-17-1401.** Definitions.

As used in this part:

- (1) "Academic research cannabis license" means the license described in Title 4, Chapter 41a, Part 9, Academic Medical Cannabis Research.
  - (2) "Cannabis" means the same as that term is defined in Section 26-61a-102.
- (3) "Cannabis cultivation facility" means the same as that term is defined in Section 4-41a-102.
  - (4) "Cannabis product" means the same as that term is defined in Section 26-61a-102.
- (5) "Center" means the Center for the Medical Cannabis Research created in Section 53B-17-1402.
  - (6) "Eligible institution" means an institution of higher education that:
  - (a) is located in Utah; and
  - (b) has or will obtain an academic research cannabis license.
- (7) "Medical cannabis patient card" means the same as that term is defined in Section 26-61a-102.

Section  $\frac{7}{6}$ . Section 53B-17-1402 is enacted to read:

#### 53B-17-1402. Center creation -- Duties.

- (1) There is created the Center for Medical Cannabis Research within the University of Utah.
  - (2) The center:
- (a) shall seek state, federal, and private funds to award grants for medical cannabis research;
- (b) shall facilitate and support funding for research related to the health effects, including the potential risks or side effects, of the use of cannabis products;

- (c) shall facilitate and support funding for research related to the efficacy and potential health effects of various cannabis delivery methods, including vaporizing, ingesting, topical application, and combustion;
- (d) shall support researchers in applying for and securing federal and private research grant funding for expanding medical cannabis research;
- (e) shall review current and future cannabis research literature, clinical studies, and clinical trials;
- (f) shall educate medical providers, lawmakers, and the public about medical cannabis research advances;
- (g) shall, if requested, consult with researchers and eligible institutions seeking to conduct medical cannabis research regarding legal implications of the research under state and federal law;
- (h) shall monitor, to the extent that appropriate and sufficient data are available, patient outcomes in any state with a medicinal cannabis program;
  - (i) may coordinate, share knowledge, and share best practices with a state:
  - (i) that has a medical cannabis program; and
  - (ii) is conducting cannabis research;
- (j) may award or facilitate funding for grants to an eligible institution for medical cannabis research, including research regarding the growing of a medical-grade cannabis plant that is used for a cannabis product;
- (k) shall support a licensed cannabis cultivation facility to provide medical-grade cannabis products for research;
- (1) shall make { any}, for research conducted by the center, the research outcomes publicly available;
- (m) shall maintain a catalog of all published scientific reports based on projects funded or managed by the center;
- (n) shall ensure that an individual who agrees to use a cannabis product as part of a research project conducted by the center or a grantee has:
  - (i) a valid medical cannabis patient card from the state; or
- (ii) if included in the research project as a resident of another state, the equivalent of a medical cannabis patient card under the laws of another state, district, territory,

commonwealth, or insular possession of the United States;

- (o) shall obtain an academic research cannabis license;
- (p) may apply for, or assist an eligible institution to apply for, a federal cannabis cultivation registration to locate a cannabis cultivation site in Utah; and
- (q) for the report described in Section 26-61a-703, shall provide information to the Department of Health and Human Services describing:
- (i) all research projects that are funded by a grant awarded by the center, including which institution received the grant; and
  - (ii) all research projects conducted by the center.
- (3) For research funded, conducted, or facilitated by the center, the center shall ensure the research:
  - (a) includes appropriate research development, testing, and evaluation; and
- (b) if the research involves human subjects, is reviewed, approved, and overseen by an institutional review board as defined in Section 26-61-102.

(<del>13</del>) The University of Utah shall provide staff for the center.

```
Section 8. Repealer.

This bill repeals:

Section 26-61-101, Title.

Section 26-61-102, Definitions.

Section 26-61-103, Institutional review board -- Approved study of cannabis, a cannabinoid product, or an expanded cannabinoid product.

Section 26-61-201, Cannabis Research Review Board.

Section 26-61-202, Duties.
```